Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The price of Caredx Inc (NASDAQ: CDNA) closed at $17.81 in the last session, down -0.50% from day before closing price of $17.9. In other words, the price has decreased by -$0.50 from its previous closing price. On the day, 0.57 million shares were traded. CDNA stock price reached its highest trading level at $18.05 during the session, while it also had its lowest trading level at $17.5001.
Ratios:
We take a closer look at CDNA’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.72 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 24.70. For the most recent quarter (mrq), Quick Ratio is recorded 2.75 and its Current Ratio is at 3.03. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
On January 15, 2025, Wells Fargo Upgraded its rating to Equal Weight which previously was Underweight and also lowered its target price recommendation from $28 to $24.
On August 28, 2024, Wells Fargo started tracking the stock assigning a Underweight rating and target price of $28.Wells Fargo initiated its Underweight rating on August 28, 2024, with a $28 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 07 ’25 when Novack Jeffrey Adam sold 2,688 shares for $15.52 per share. The transaction valued at 41,723 led to the insider holds 105,218 shares of the business.
Jeffrey Adam Novack bought 2,688 shares of CDNA for $40,347 on Nov 07 ’25. On Nov 05 ’25, another insider, ABHISHEK JAIN, who serves as the Officer of the company, bought 53,388 shares for $15.77 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDNA now has a Market Capitalization of 947971904 and an Enterprise Value of 749442304. As of this moment, Caredx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.94. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.56 while its Price-to-Book (P/B) ratio in mrq is 2.94. Its current Enterprise Value per Revenue stands at 2.093 whereas that against EBITDA is -51.08.
Stock Price History:
The Beta on a monthly basis for CDNA is 2.51, which has changed by -0.27424616 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, CDNA has reached a high of $26.37, while it has fallen to a 52-week low of $10.96. The 50-Day Moving Average of the stock is 16.37%, while the 200-Day Moving Average is calculated to be 7.36%.
Shares Statistics:
According to the various share statistics, CDNA traded on average about 1.28M shares per day over the past 3-months and 808670 shares per day over the past 10 days. A total of 51.41M shares are outstanding, with a floating share count of 46.41M. Insiders hold about 9.76% of the company’s shares, while institutions hold 97.06% stake in the company. Shares short for CDNA as of 1763078400 were 6961045 with a Short Ratio of 5.44, compared to 1760486400 on 6046844. Therefore, it implies a Short% of Shares Outstanding of 6961045 and a Short% of Float of 13.87.
Earnings Estimates
Current recommendations for the stock of the company come from 6.0 analysts. The consensus estimate for the next quarter is $0.21, with high estimates of $0.26 and low estimates of $0.16.
Analysts are recommending an EPS of between $0.72 and $0.67 for the fiscal current year, implying an average EPS of $0.69. EPS for the following year is $0.87, with 6.0 analysts recommending between $1.1 and $0.76.
Revenue Estimates
According to 8 analysts,. The current quarter’s revenue is expected to be $102.58M. It ranges from a high estimate of $103.13M to a low estimate of $102M. As of. The current estimate, Caredx Inc’s year-ago sales were $86.58MFor the next quarter, 8 analysts are estimating revenue of $100.63M. There is a high estimate of $102.01M for the next quarter, whereas the lowest estimate is $97.89M.
A total of 8 analysts have provided revenue estimates for CDNA’s current fiscal year. The highest revenue estimate was $374.55M, while the lowest revenue estimate was $373.4M, resulting in an average revenue estimate of $374M. In the same quarter a year ago, actual revenue was $333.79MBased on 8 analysts’ estimates, the company’s revenue will be $416.99M in the next fiscal year. The high estimate is $428.3M and the low estimate is $399.2M.
